Isabelle Ray-Coquard

Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer (2010)

Belbaraka, Rhizlane, Trédan, Olivier, Ray-Coquard, Isabelle, Chvetzoff, Giselle, Bajard, Agathe, Pérol, David, ...

Abstract Background Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I...

Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region (2010)

Lurkin, Antoine, Ducimetière, Francoise, Vince, Dominique, Decouvelaere, Anne-Valérie, Cellier, Dominic, Gilly, François N, ...

Abstract Background Sarcomas are rare malignant tumors. Accurate initial histological diagnosis is essential for adequate management. We prospectively assessed the medical management of all patients...

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) (2009)

Sleijfer, Stefan ; JFA; CORA, Ray-Coquard, Isabelle, Papai, Zsuzsa, Le Cesne, Axel, Scurr, Michelle, Schöffski, Patrick; U0046480 ;, ...

PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived...

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment (2008)

Perrier, Lionel, Cautela, Nicola, Morelle, Magali, Havet, Nathalie, Ducimetière, Françoise, Lurkin, Antoine, ...

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified. Objective: To estimate relationships between medical...

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment (2008)

Perrier, Lionel, Cautela, Nicola, Morelle, Magali, Havet, Nathalie, Ducimetière, Françoise, Lurkin, Antoine, ...

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified. Objective: To estimate relationships between medical...

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment (2008)

Perrier, Lionel, Cautela, Nicola, Morelle, Magali, Havet, Nathalie, Ducimetière, Françoise, Lurkin, Antoine, ...

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified.Objective: To estimate relationships between medical...

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment (2008)

Perrier, Lionel, Cautela, Nicola, Morelle, Magali, Havet, Nathalie, Ducimetière, Françoise, Lurkin, Antoine, ...

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified.Objective: To estimate relationships between medical...

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment (2008)

Perrier, Lionel, Cautela, Nicola, Morelle, Magali, Havet, Nathalie, Ducimetière, Françoise, Lurkin, Antoine, ...

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified.Objective: To estimate relationships between medical...

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment (2008)

Perrier, Lionel, Cautela, Nicola, Morelle, Magali, Havet, Nathalie, Ducimetière, Françoise, Lurkin, Antoine, ...

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified.Objective: To estimate relationships between medical...

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study (2005)

Van Glabbeke, Martine ; JFA; CORA, Verweij, Jaap, Casali, Paolo G, Le Cesne, Axel, Hohenberger, Peter, Ray-Coquard, Isabelle, ...

PURPOSE: The aim of this study was to identify factors predicting initial and late resistance of GI stromal tumor (GIST) patients to imatinib and to document the dose-response relationship in the...

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment

Lionel Perrier, Nicola Cautela, Magali Morelle, Nathalie Havet, Françoise Ducimetière, Antoine Lurkin, ...

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified.Objective: To estimate relationships between medical...